Aclaris Therapeutics Inc - Asset Resilience Ratio
Aclaris Therapeutics Inc (ACRS) has an Asset Resilience Ratio of 40.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Aclaris Therapeutics Inc (ACRS) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Aclaris Therapeutics Inc's Asset Resilience Ratio has changed over time. See Aclaris Therapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Aclaris Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACRS market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $70.66 Million | 40.25% |
| Total Liquid Assets | $70.66 Million | 40.25% |
Asset Resilience Insights
- Very High Liquidity: Aclaris Therapeutics Inc maintains exceptional liquid asset reserves at 40.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aclaris Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Aclaris Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Aclaris Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 40.41% | $89.02 Million | $220.33 Million | +0.27pp |
| 2023-12-31 | 40.13% | $79.23 Million | $197.41 Million | -27.54pp |
| 2022-12-31 | 67.67% | $172.29 Million | $254.60 Million | +2.36pp |
| 2021-12-31 | 65.31% | $164.06 Million | $251.21 Million | +20.01pp |
| 2020-12-31 | 45.30% | $32.07 Million | $70.78 Million | +5.55pp |
| 2019-12-31 | 39.76% | $39.08 Million | $98.30 Million | -0.51pp |
| 2018-12-31 | 40.26% | $110.95 Million | $275.57 Million | -31.05pp |
| 2017-12-31 | 71.31% | $173.66 Million | $243.51 Million | +10.52pp |
| 2016-12-31 | 60.80% | $107.05 Million | $176.09 Million | -18.95pp |
| 2015-12-31 | 79.74% | $75.02 Million | $94.08 Million | +48.82pp |
| 2014-12-31 | 30.92% | $5.37 Million | $17.38 Million | +4.62pp |
| 2013-12-31 | 26.30% | $3.74 Million | $14.21 Million | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more